MYX (MYXFinance) experiences 40.7% volatility in 24 hours: High trading volume followed by a brief rebound and rapid decline
Bitget Pulse2026/04/19 04:42Volatility Brief
In the past 24 hours, the price of MYX peaked at $0.3057 and dropped to a low of $0.2173, with the current quote at $0.2173, resulting in a price range of 40.7%. The 24-hour trading volume surged significantly to about $57.41 million (CMC data) or $46.52 million (CoinGecko data), both exceeding its market cap (around $43.4 million-$63.4 million). Capital flows remained active, but were accompanied by an overall decline of -14% to -17%.
Brief Analysis of the Reasons for the Movement
- There have been no official announcements or major news events in the past 24 hours, but a spike in trading volume (several times higher than usual) drove the price to briefly rebound near $0.30 before quickly falling back. This may be attributed to speculative trading in leveraged perpetual contracts and the inflow of bullish capital.
- On-chain TVL remains at $16.96 million, with DEX trading volume around $3.3 million, and there are no records of significant whale transfers or alerts.
(Compared to the 109% surge on April 14-15, which was mainly driven by a 300% spike in trading volume and increased interest in holding positions that triggered a short squeeze, this time reflects a continuation of similar volatility.)
Market Perspectives and Outlook
The community's prevailing sentiment is cautious. Discussions on X platform have often attributed MYX's recent volatility to "manipulation and whale coordination," similar to the RAVE collapse case. There is concern about dumping risk after a pump; analysts warn that high-leverage funding rates and concentrated positions may lead to further liquidations, with high volatility likely persisting in the short term. Support is around $0.22.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
